Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens

Articles

SCIENCE AT A GLANCE Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens Scientists at Calviri and MD Anderson Cancer Center, have studied a distinct source of cancer-specific biomarkers: antibodies to neoantigens generated by translation of RNA-level errors. In all cells, errors in RNA transcription and processing occur more than 100-fold more…

Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency

Articles

SCIENCE AT A GLANCE  Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency Patients with autosomal recessive NIK or RELB deficiency, or a specific type of autosomal-dominant NF-κB2 deficiency, have neutralizing autoantibodies against type I IFNs and are at higher risk of getting life-threatening COVID-19 pneumonia. In contrast to patients with autoimmune…